In 1996 the International Committee for Taxonomy of Viruses (ICTV) recognized the name Nidovirales, as the formal name for Coronaviridae and A rteriviridae. In recognition of this change, and in response to the wishes of our colleagues we named this meeting for the first time "The International Symposium of Nidoviruses". The meeting in the wooded environment of Lake Harmony, Pennsylvania, provided a stimulating opportunity for assessing the progress made in the field since the last meeting in Segovia Spain in 1997. Over 150 scientists from academia and industry attended the meeting. The meeting hosted senior members of the Nidovirus community, some of whom have been studying the subject for over 20 years, as well as younger scientists, the next generation of Nidoviro10gists. The traditional informal format, the shared meals, the social activities and the relatively inexpensive venue made the meeting a popular adventure. In her opening remarks Susan Weiss showed pictures from previous meetings, reminding us how young we used to look. Neal Nathanson was our keynote speaker at the opening night, giving an overview on how viral pathogenesis studies helped in shaping the evolution of viral research and vaccine development. The scientific program of the meeting was divided into 9 sessions including lO keynote presentations. The meeting opened with a session on epidemiology, evolution and genome structure. Sasha Gorbalenya shared with us insights gained from comparative sequence analysis, emphasizing the unifying traits among nidovriuses, but also pointed out the remaining "black holes".

Multiple Sclerosis (MS) is an enigmatic immune mediated disease of the central nervous system that affects about 350,000 individuals in the US, and many more around the world. The mechanism of this disease is largely unknown and there is no cure for it. However, there are several well-characterized experimental animal models that help us understand and speculate about potential mechanisms of pathology in this disease. Many of the experimental therapies designed for this disease rely on testing the drugs in animal models before using it in clinical trials. This book combines for the first time the different experimental models for MS (including immune-mediated and viral) under one roof, and highlights aspects that are different or shared among these experimental models. It 's aim is to improve our understanding of this devastating disease and help us think about potential additional therapies for it.